Erschienen in:
01.08.2006 | Erratum
Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients
verfasst von:
F. J. Peñalver, V. Jimenez-Yuste, M. Almagro, A. Alvarez-Larrán, L. Rodríguez, M. Casado, L. Gallur, P. Giraldo, R. Hernández, D. Menor, M. J. Rodríguez, D. Caballero, R. González, J. Mayans, I. Millán, J. R. Cabrera, On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP
Erschienen in:
Annals of Hematology
|
Ausgabe 8/2006
Einloggen, um Zugang zu erhalten
Excerpt
In the subsection “Factors associated with response”, the following incorrect statement was made: “In this group, it was observed that four maintained CR (3 patients that had received three doses and 1 patient that have received one dose).” …